Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
| NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
Jefferies London Healthcare Conference Date: Thursday, November 19, 2020 Piper Sandler 32nd Annual Healthcare Conference Management will participate in a fireside chat, which will be accessible beginning on November 23, 2020, via the “Investors” section of the company’s website: www.relmada.com. The link will remain active for 90 days thereafter. About Relmada Therapeutics, Inc. Relmada Therapeutics is a late-stage pharmaceutical company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’ s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, and is entering late-stage studies as an adjunctive treatment for MDD in adults. Investor Contact: Media Inquiries:
SOURCE Relmada Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:RLMD |
View original content to download multimedia:
